Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dupilumabum - injektionslösung in fertigpen vorausgefüllt - dupilumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 2 ml corresp. natrium 0.45 mg. - dermatite atopique modérée à sévère, asthme, polypose naso-sinusienne, prurigo nodularis et œsophagite à éosinophiles. - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dupilumabum - injektionslösung in einer fertigspritze mit sicherheitssystem - dupilumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, natrii acetas trihydricus, acidum aceticum glaciale, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.67 ml, natrium 0.15 mg. - dermatite atopique modérée à sévère, asthme, polypose naso-sinusienne, prurigo nodularis et œsophagite à éosinophiles - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 30 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 60 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.4 ml. - hämophilie a - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 105 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.7 ml. - hämophilie a - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 150 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - medikamente für obstruktive atemwegserkrankungen, - allergische asthmaxolair ist indiziert bei erwachsenen, jugendlichen und kindern (6 bis.

Europäische Union - Deutsch - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - arthritis, rheumatoide - immunsuppressiva - kevzara in kombination mit methotrexat (mtx) ist indiziert für die behandlung von mäßig bis stark aktiver rheumatoider arthritis (ra) bei erwachsenen patienten, die haben nur unzureichend beantwortet, oder wer sind intolerant gegenüber einem oder mehreren krankheitsmodifizierende anti-rheumatische drogen (dmards). kevzara kann als monotherapie bei intoleranz gegenüber mtx oder bei behandlung mit mtx angewendet werden.

Europäische Union - Deutsch - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration limited - emicizumab - hämophilie a - antihämorrhagika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kann verwendet werden in allen altersgruppen.